Information Provided By: 
Fly News Breaks for July 29, 2015
MYL
Jul 29, 2015 | 13:11 EDT
BTIG said recent weakness in Mylan (MYL) following Teva's (TEVA) announcement to acquire Allergan's (AGN) generic segment is a buying opportunity. The firm believes Mylan management will need to find ways boost its stock price ahead of the scheduled August 28 shareholder meeting in order for a Perrigo (PRGO) deal to be completed. With Q2 earnings scheduled for August 6, BTIG expects a solid quarter to be reported, with revenues of $2.34B and adjusted earnings of $0.88.
News For MYL From the Last 2 Days
There are no results for your query MYL
